News & Events

Upcoming Events

Tue, 2/14/2023 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Thu, 2/16/2023 - 6:30 PM ET
For patients/survivors General meetup for those impacted by lung… more
Tue, 2/21/2023 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Thu, 2/23/2023 - 8:00 PM ET
For caregivers, family & friends - You don’t need to take on… more
Tue, 2/28/2023 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more

Innovative Research Brings Potential New Class of Drugs for Patients with ALK-EML4 Fusion

Innovative Research Brings Potential New Class of Drugs for Patients with ALK-EML4 Fusion

Targeted therapies, or treatments directed towards specific biomarkers in tumor cells, have been effective in treating many patients with advanced-stage non-small cell lung cancer (NSCLC). Tumors that have the ALK protein fused with another cancer-driving protein, such as the EML4 protein, are often referred to as ALK-positive tumors. Approximately 5% of advanced-stage adenocarcinoma, a type of NSCLC, will test positive for an ALK-fusion biomarker. Treating patients with ALK-positive lung…

Thriving with Cancer, with Dann Wonser

Thriving with Cancer, with Dann Wonser

Dann Wonser, a 16-year lung cancer survivor and author of the book Second Wind – Thriving with Cancer, joins LUNGevity's Angela James to share learnings from his cancer journey and the tactics he's used to not only survive but thrive with lung cancer. Visit Dann's website to read his blog or purchase your own copy of Second Wind - Thriving with Cancer at www.dannwonser.com.   <Back to the Patient Gateways

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

Takeda's Exkivity to compete against Janssen's Rybrevant in rare NSCLC treatment market

Takeda's Exkivity to compete against Janssen's Rybrevant in rare NSCLC treatment market

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

Shared Decision-Making, Self-Advocacy, and Dealing with Financial Toxicity

Shared Decision-Making, Self-Advocacy, and Dealing with Financial Toxicity

Cardinale Smith, MD, PhD, oncologist and associate professor at the Icahn School of Medicine at Mt. Sinai, explains how shared decision-making with one's healthcare team can create a treatment plan that aligns with the patient's goals. This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.   <Back to the Patient Gateways

The Benefits of Palliative Care for People Living with Lung Cancer

The Benefits of Palliative Care for People Living with Lung Cancer

Palliative care is supportive care that anticipates, prevents, and treats the symptoms and side effects of the disease and its treatment. It is intended to improve one's quality of life and can be addressed at any stage from diagnosis forward. This webinar features Estelamari Rodriguez, MD, MPH, thoracic oncologist at the Sylvester Comprehensive Cancer Center at the University of Miami. This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.   <Back to the…

Raise Your Voice: Speaking Up About Living With Lung Cancer

Raise Your Voice: Speaking Up About Living With Lung Cancer

An online panel discussion offers real-world suggestions and examples for ways to get the care and support you need. The discussion features Angela James, LUNGevity care navigator;  Lavern McDonald, a teacher living with lung cancer; and Patricia Simmers, a nurse navigator. The panelists share their personal stories, challenges, and lessons learned through their journeys with lung cancer. This panel discussion was hosted by LUNGevity in collaboration with Novartis.

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC